American National Bank & Trust Sells 532 Shares of Eli Lilly and Company $LLY

Posted by Geri Gentry on Oct 7th, 2026

Eli Lilly and Company logo American National Bank & Trust trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 3.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,343 shares of the company’s stock after selling 532 shares during the quarter. Eli Lilly and Company makes up approximately 1.6% of American National Bank & Trust’s investment portfolio, making the stock its 19th largest position. American National Bank & Trust’s holdings in Eli Lilly and Company were worth $17,753,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Integrity Financial Corp WA increased its holdings in shares of Eli Lilly and Company by 1.3% in the second quarter. Integrity Financial Corp WA now owns 639 shares of the company’s stock worth $767,000 after purchasing an additional 8 shares during the last quarter. Willner & Heller LLC grew its stake in shares of Eli Lilly and Company by 1.0% in the 2nd quarter. Willner & Heller LLC now owns 917 shares of the company’s stock worth $1,100,000 after buying an additional 9 shares in the last quarter. Aspiring Ventures LLC grew its position in Eli Lilly and Company by 3.7% in the second quarter. Aspiring Ventures LLC now owns 255 shares of the company’s stock worth $306,000 after acquiring an additional 9 shares in the last quarter. Wealthspan Partners LLC boosted its holdings in shares of Eli Lilly and Company by 0.4% in the 2nd quarter. Wealthspan Partners LLC now owns 2,120 shares of the company’s stock worth $2,543,000 after purchasing an additional 9 shares during the period. Finally, Navigoe LLC lifted its position in Eli Lilly and Company by 8.7% in the second quarter. Navigoe LLC now owns 113 shares of the company’s stock worth $135,000 after buying an additional 9 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock worth $15,958,170 in the last three months. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded up $40.05 during midday trading on Wednesday, hitting $1,197.54. The company had a trading volume of 1,165,722 shares, compared to its average volume of 2,967,986. The stock has a market cap of $1.13 trillion, a price-to-earnings ratio of 40.19, a PEG ratio of 1.40 and a beta of 0.46. Eli Lilly and Company has a 12-month low of $783.85 and a 12-month high of $1,292.65. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The company has a fifty day simple moving average of $1,173.98 and a 200 day simple moving average of $1,092.69.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm’s revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the firm earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, analysts predict that Eli Lilly and Company will post 36.66 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

LLY has been the subject of several recent analyst reports. Morgan Stanley boosted their target price on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the company an “overweight” rating in a research report on Wednesday. Sanford C. Bernstein lifted their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a report on Tuesday, July 14th. Jefferies Financial Group lifted their price target on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research note on Tuesday, June 9th. Guggenheim lifted their target price on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a research report on Friday, September 18th. Finally, Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, August 26th. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,312.36.

Check Out Our Latest Research Report on LLY

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Strong GLP-1 growth outlook: Analysts remain constructive on Lilly’s Mounjaro and Zepbound franchises, while anticipated momentum from the oral GLP-1 candidate Foundayo could support growth in the second half of 2026. Recent data presented at a diabetes meeting showed Foundayo produced greater weight loss and better blood-sugar control than oral semaglutide in adults with type 2 diabetes, although commercial and regulatory execution remain important. Eli Lilly’s Breakout May Occur Soon – H2’26 Foundayo Tailwinds
Positive Sentiment: Pipeline diversification: Lilly is working to reduce reliance on obesity and diabetes products through oncology, immunology, neuroscience, and other areas. The FDA granted orphan-drug designation to experimental cancer treatment olomorasib, providing potential development incentives and exclusivity benefits. Lilly also expanded its drug-discovery collaboration with Gate Bioscience in a deal potentially worth more than $870 million. Eli Lilly Stock Gains on Regulatory Win
Positive Sentiment: Additional development progress: Early-stage updates for eltrekibart and a new basal-insulin candidate point to continued investment in Lilly’s pipeline. Its partnership with insitro is also making machine-learning tools available through Lilly TuneLab, potentially improving external drug discovery and future licensing opportunities. Lilly’s New Basal Insulin Candidate Clears Key Early Trial Milestone
Neutral Sentiment: Upcoming earnings focus: Investor attention is building ahead of third-quarter results. Recent coverage points to improving operating momentum, but expectations are already high following the company’s prior revenue and earnings outperformance.
Negative Sentiment: Valuation and concentration risks: Commentary warns that Lilly trades at a substantial premium to the broader market, leaving limited room for disappointing sales, pricing, or guidance. Falling U.S. prices for Zepbound and Mounjaro could also pressure future margins or growth assumptions. Eli Lilly: Impressive Growth, Questionable Valuation
Negative Sentiment: Childhood-obesity guidance: New World Health Organization guidelines discourage certain approaches to treating childhood and adolescent obesity, creating potential uncertainty around how quickly GLP-1 therapies could expand in younger populations. WHO Childhood Obesity Guidelines

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.